GNLX Stock Summary and Trading Ideas (Genelux | NASDAQ:GNLX)

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Genelux trades on the NASDAQ stock market under the symbol GNLX.

As of March 10, 2025, GNLX stock price declined to $3.78 with 202,140 million shares trading.

GNLX has a beta of 0.15, meaning it tends to be less sensitive to market movements. GNLX has a correlation of 0.00 to the broad based SPY ETF.

GNLX has a market cap of $130.54 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that GNLX belongs to (by Net Assets): VTI, VXF, CNCR, IWC, AVSC.

GNLX has underperformed the market in the last year with a price return of -41.0% while the SPY ETF gained +10.3%. However, in the short term, GNLX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +39.5% vs -7.4% return in SPY. But in the last 2 weeks, GNLX shares have been beat by the market, returning -21.4% compared to an SPY return of -6.6%.

GNLX support price is $3.82 and resistance is $4.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNLX shares will trade within this expected range on the day.